Results 171 to 180 of about 370,708 (316)

Enhancer Activation During Early Embryonic Development

, 2017
Gene, die stark transkribiert werden und eine große Rolle in der Embryonalentwicklung spielen, sind oft mit Enhancer-cluster, Super-enhancer, die die Genexpression antreiben, assoziiert.
Geyer, Marlene
core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Tumor-specific super-enhancer drives overexpression of EVI1/MECOM in ovarian cancer. [PDF]

Neoplasia
Kruse S, Kiehlmeier S, Mika J, Havermans M, Mulet-Lazaro R, Vašíčková K, Timmermans M, van Herk S, Herrmann C, Quintero A, Beverloo HB, Jansen M, Groenendijk FH, Boere I, Martens JWM, Delwel R, Gröschel S, Scholl C, Fröhling S, Smeenk L.   +19 more
europepmc   +1 more source

TOPOLOGICAL REGULATION OF ENHANCER-PROMOTER COMMUNICATION

, 2019
The activation of gene expression by transcriptional enhancers remains a central mystery in molecular biology. One prevailing view has been that enhancers loop directly to the promoters of genes they regulate in a targeted fashion.
Heist, Tyler
core  

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Regulatory activity and evolutionary co-option of cis-regulatory elements underlying bear hibernation. [PDF]

Mol Biol Evol
Perry BW, Ryan K, McGowan KL, Wooldridge TB, Savenkova M, Duttke SH, Jansen HT, Robbins CT, Kelley JL.   +8 more
europepmc   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

A prostate cancer-specific super-enhancer at 1q42.3 regulates the CAPN2 and KRT19. [PDF]

J Biol Chem
Zhao Z, Bai Y, Wang Q, Zhao Y, Jiang Y, Li H, Yang Z, Liu X, Zhang L, Zhao Z, Qian Y, Li P, Shi J, Lu W.   +13 more
europepmc   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining

Molecular Oncology, EarlyView.
IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis, Jack V. Mills, Wojciech Niedzwiedz, Valentine M. Macaulay   +3 more
wiley   +1 more source